BID Equity acquires AB CUBE, a leading software provider for pharmaceutical product safety
BID Equity Fund II, advised by BID Equity, has acquired AB CUBE, SAS based in Paris, an established provider of multivigilance software in the pharmaceutical and cosmetics sectors.
With its SafetyEasy® Suite, AB CUBE offers its customers a simple and regulatory-compliant solution for reporting and processing vigilance processes. In addition to the recording of adverse reactions for combination products, AB CUBE covers a variety of other areas, such as biovigilance or cosmetovigilance. This combination offers manufacturers and marketing authorization holders the possibility to standardize their vigilance processes across different product areas and to ensure permanent compliance with the regulatory requirements of FDA, EMA and MHRA. More than 2000 users in over 43 countries currently manage their vigilance processes with the AB CUBE SafetyEasy® Suite.
With AB CUBE as the cornerstone, the development of a new group of companies in the field of medical, pharmaceutical and cosmetic regulatory and safety processes begins. The objective is to build a provider that covers all relevant international regulatory compliance – incl. vigilance – needs. AB CUBE Managing Director Matthieu Doresse emphasizes: "BID Equity's expertise both in software development and clinical research processes makes them a perfect partner to accelerate the internationalization of AB CUBE. I look forward to jointly build the leading software provider for regulatory affairs in the medical space in Europe."